Evaluation of the molecular Xpert Xpress Flu/RSV assay vs. Alere i Influenza A & B assay for rapid detection of influenza viruses

Diagn Microbiol Infect Dis. 2018 Mar;90(3):177-180. doi: 10.1016/j.diagmicrobio.2017.11.010. Epub 2017 Nov 24.

Abstract

A new FDA-approved Xpert Xpress Flu/RSV assay has been released for rapid influenza virus detection. We collected 134 nasopharyngeal specimens to compare the diagnostic performance of the Xpert assay and the Alere i Influenza A & B assay for influenza A and B virus detection. The Xpert assay demonstrated 100% and 96.3% sensitivity to influenza A and influenza B virus respectively. Its specificity was 100% for both viruses. The Alere i assay demonstrated slightly lower sensitivity but similar specificity to the Xpert Xpress assay. Although the Xpert assay (30 min) required longer processing time than the Alere assay (15 min), the handling procedure of the Alere assay was more complicated than the Xpert assay. As the GenXpert system has higher throughput than the Alere system, it is more suitable for hospital clinical laboratories. Overall, the new Xpert Xpress Flu/RSV assay is a reliable and useful tool for rapid influenza detection.

Keywords: Alere i Flu A & B; Influenza virus; Rapid molecular test; Xpert Xpress Flu/RSV.

Publication types

  • Comparative Study

MeSH terms

  • Humans
  • Influenza A virus / genetics*
  • Influenza A virus / isolation & purification
  • Influenza B virus / genetics*
  • Influenza B virus / isolation & purification
  • Influenza, Human / diagnosis*
  • Influenza, Human / virology
  • Laboratories, Hospital
  • Molecular Diagnostic Techniques / methods*
  • Real-Time Polymerase Chain Reaction / methods
  • Sensitivity and Specificity